Oppenheimer lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $350 from $375 and keeps an Outperform rating on the ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of $350.00. The company’s shares closed yesterday at $203.59.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has successfully completed enrollment for its MAESTRO-NASH OUTCOMES trial, a ...

The Janus Henderson Biotech Innovation Fund continues to lead all biopharma and life sciences hedge funds after mixed results for the general strategy in September. Several funds lost money last month ...

With the FDA approval this year of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) as a treatment for metabolic dysfunction-associated steatohepatitis (MASH), also known as nonalcoholic ...

CEST Biocartis announces six Idylla™ abstracts to be presented at AMP 2024 Annual Meeting Mechelen, Belgium, 23 October 2024 ...

Peloton plans to sell its deluxe stationary bike at Costco this holiday season as the struggling connected-exercise company ...

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 106,050.50 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue ...